JP2018509890A - 人工多能性幹細胞（ｉＰＳＣ）の生産を再プログラムする方法 - Google Patents

人工多能性幹細胞（ｉＰＳＣ）の生産を再プログラムする方法 Download PDF

Info

Publication number
JP2018509890A
JP2018509890A JP2017540262A JP2017540262A JP2018509890A JP 2018509890 A JP2018509890 A JP 2018509890A JP 2017540262 A JP2017540262 A JP 2017540262A JP 2017540262 A JP2017540262 A JP 2017540262A JP 2018509890 A JP2018509890 A JP 2018509890A
Authority
JP
Japan
Prior art keywords
δ133p53β
isoform
cells
δ133p53γ
ipsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017540262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509890A5 (enExample
Inventor
ルー　ピエール
ピエール ルー
Original Assignee
センター ナショナル ド ラ ルシェルシュ サイエンティフィーク
センター ナショナル ド ラ ルシェルシュ サイエンティフィーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センター ナショナル ド ラ ルシェルシュ サイエンティフィーク, センター ナショナル ド ラ ルシェルシュ サイエンティフィーク filed Critical センター ナショナル ド ラ ルシェルシュ サイエンティフィーク
Publication of JP2018509890A publication Critical patent/JP2018509890A/ja
Publication of JP2018509890A5 publication Critical patent/JP2018509890A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
JP2017540262A 2015-01-30 2016-02-01 人工多能性幹細胞（ｉＰＳＣ）の生産を再プログラムする方法 Pending JP2018509890A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305145 2015-01-30
EP15305145.3 2015-01-30
PCT/EP2016/052085 WO2016120493A1 (en) 2015-01-30 2016-02-01 Reprogramming method for producing induced pluripotent stem cells (ipsc)

Publications (2)

Publication Number Publication Date
JP2018509890A true JP2018509890A (ja) 2018-04-12
JP2018509890A5 JP2018509890A5 (enExample) 2019-03-14

Family

ID=52589314

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540262A Pending JP2018509890A (ja) 2015-01-30 2016-02-01 人工多能性幹細胞（ｉＰＳＣ）の生産を再プログラムする方法

Country Status (4)

Country Link
US (1) US10767165B2 (enExample)
EP (1) EP3250679B1 (enExample)
JP (1) JP2018509890A (enExample)
WO (1) WO2016120493A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022534295A (ja) * 2019-05-30 2022-07-28 イミュノルクス インターナショナル コーポレーション ワクチン接種及び疾患治療法のための自己人工多能性幹細胞とのポックスウイルスの使用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845960B2 (en) 2016-09-12 2023-12-19 President And Fellows Of Harvard College Transcription factors controlling differentiation of stem cells
WO2018064460A1 (en) * 2016-09-30 2018-04-05 Mayo Foundation For Medical Education And Research Viral vectors for nuclear reprogramming
WO2018204262A1 (en) * 2017-05-01 2018-11-08 President And Fellows Of Harvard College Transcription factors controlling differentiation of stem cells
GB2564437B (en) * 2017-07-10 2020-11-04 Univ Brunel Method of testing a gene therapy vector using induced pluripotent stem cells
WO2019108894A1 (en) 2017-12-01 2019-06-06 President And Fellows Of Harvard College Methods and compositions for the production of oligodendrocyte progenitor cells
US11788131B2 (en) 2018-04-06 2023-10-17 President And Fellows Of Harvard College Methods of identifying combinations of transcription factors
GB201909975D0 (en) * 2019-07-11 2019-08-28 Babraham Inst Novel reprogramming method
US20220273591A1 (en) * 2019-07-26 2022-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining risk of developing insulin resistance
CN114736872A (zh) * 2022-05-06 2022-07-12 中国科学院动物研究所 提高多能干细胞性能的组合物、方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531606A (ja) * 2009-06-30 2012-12-10 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） Δ１３３ｐ５３βを用いた転移癌を有する素因があると思われる被験体の検査方法
JP2013541951A (ja) * 2010-10-01 2013-11-21 アメリカ合衆国 ｐ５３アイソフォームによる幹細胞機能の操作
JP2018506278A (ja) * 2015-01-30 2018-03-08 センター ナショナル ド ラ ルシェルシュ サイエンティフィーク デルタ１３３ｐ５３ベータおよびデルタ１３３ｐ５３ガンマアイソフォームはがん幹細胞のバイオマーカーである

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2690554T3 (es) * 2008-03-17 2018-11-21 The Scripps Research Institute Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas
KR101606943B1 (ko) * 2008-06-27 2016-03-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
WO2010033991A2 (en) * 2008-09-22 2010-03-25 Children's Medical Center Corporation Detection of human somatic cell reprogramming
WO2011016588A1 (en) * 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531606A (ja) * 2009-06-30 2012-12-10 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） Δ１３３ｐ５３βを用いた転移癌を有する素因があると思われる被験体の検査方法
JP2013541951A (ja) * 2010-10-01 2013-11-21 アメリカ合衆国 ｐ５３アイソフォームによる幹細胞機能の操作
JP2018506278A (ja) * 2015-01-30 2018-03-08 センター ナショナル ド ラ ルシェルシュ サイエンティフィーク デルタ１３３ｐ５３ベータおよびデルタ１３３ｐ５３ガンマアイソフォームはがん幹細胞のバイオマーカーである

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARSIC N. ET AL., STEM CELL REPORTS, vol. Vol.4 [Epub 2015 Mar 5], JPN6020011440, pages 531 - 540, ISSN: 0004240066 *
BOURDON J. ET AL., GENES & DEVELOPMENT, vol. 19 (2005), JPN6020011439, pages 2122 - 2137, ISSN: 0004446041 *
MAHERALI N. ET AL., CELL STEM CELL, vol. 3 (2008), JPN6020011438, pages 595 - 605, ISSN: 0004446042 *
MONTSERRAT N. ET AL., J. BIOL. CHEM., vol. Vol.287 No.29 (2012), JPN6021004853, pages 24131 - 24138, ISSN: 0004446043 *
POPOWSKI M. ET AL., STEM CELL REPORTS, vol. Vol.2 (2014), JPN6021004858, pages 26 - 35, ISSN: 0004446044 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022534295A (ja) * 2019-05-30 2022-07-28 イミュノルクス インターナショナル コーポレーション ワクチン接種及び疾患治療法のための自己人工多能性幹細胞とのポックスウイルスの使用

Also Published As

Publication number Publication date
EP3250679A1 (en) 2017-12-06
US10767165B2 (en) 2020-09-08
US20180023056A1 (en) 2018-01-25
WO2016120493A1 (en) 2016-08-04
EP3250679B1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
US10767165B2 (en) Reprogramming method for producing induced pluripotent stem cells (iPSC)
JP7051748B2 (ja) 細胞を幼若化するための方法
CN101617043B (zh) 核重编程方法
CN102317448B (zh) 多能细胞/多潜能细胞及方法
JP7501824B2 (ja) より未分化状態への細胞の誘導方法
JP5633075B2 (ja) 多能性幹細胞作成用ベクター材料及びこれを用いた多能性幹細胞作成方法
WO2010013359A1 (en) Efficient method for establishing induced pluripotent stem cells
JP6264670B2 (ja) 幹細胞における腫瘍化原因細胞の除去方法
KR20140004724A (ko) 전분화능을 위한 선천적 잠재력을 갖는 체세포
US20210147869A1 (en) Reprogramming vectors
WO2018113145A1 (zh) 一种同时抵抗细胞衰老及恶性转化的人多能干细胞的制备方法
Chichagova et al. Generation of human induced pluripotent stem cells using RNA-based Sendai virus system and pluripotency validation of the resulting cell population
JP5856949B2 (ja) 人工多能性幹細胞の製造方法
CN104726496B (zh) 携带人类成年早衰症基因突变的多能干细胞及制备方法
Tashiro et al. Efficient adenovirus vector‐mediated PPAR gamma gene transfer into mouse embryoid bodies promotes adipocyte differentiation
WO2022220146A1 (ja) Ｔ細胞受容体遺伝子を導入するためのｉＰＳ細胞により構成される細胞バンク
Chang et al. Immortalization of human umbilical vein endothelial cells with telomerase reverse transcriptase and simian virus 40 large T antigen
JP5924741B2 (ja) 人工癌幹細胞の作製方法及びその分化誘導方法
JP6044932B2 (ja) 幹細胞の安定的維持、複製を制御するためのペプチジルプロリルイソメラーゼＰｉｎ１の利用
KR101649709B1 (ko) 역분화줄기세포 제조 방법
WO2025220751A1 (ja) 薬剤依存的な細胞死誘導可能不死化細胞及びその作製方法
WO2011068159A1 (ja) 多能性幹細胞の製造のための核酸
CN118222633A (zh) 诱导成纤维细胞转分化为肾小管上皮细胞的方法及产品
WO2011145615A1 (ja) 多能性幹細胞の製造のための核酸
Mayers Engineering Red Blood Cell Progenitors to Achieve Greater Proliferative Potential

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210218